Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
---|
11/29/2001 | WO2001089518A1 Method of determining a dosage of anti-oxidant for an individual |
11/29/2001 | WO2001089510A2 Use of an ampa receptor potentiator for the treatment of obesity |
11/29/2001 | WO2001089494A2 Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases |
11/29/2001 | WO2001089451A2 Protease inhibitors |
11/29/2001 | WO2001089319A2 Tryptophan source from plants and uses therefor |
11/29/2001 | WO2001070695A8 Pyridine derivatives as inhibitors of p38 |
11/29/2001 | WO2001060835A8 Purine derivatives |
11/29/2001 | WO2001055115A8 Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof |
11/29/2001 | WO2001049674A3 Glycosidase inhibitors and preparation thereof |
11/29/2001 | WO2001049305A3 Process for obtaining thylakoids from plants, pure thylakoids and use thereof |
11/29/2001 | WO2001042471A8 Polypeptides and polynucleotides encoding same |
11/29/2001 | WO2001038566A3 Screening method for candidate drugs |
11/29/2001 | WO2001035096A3 Diseases associated with altered mitochondrial function |
11/29/2001 | WO2001028567A3 Aminoalkylenephosphonates for treatment of bone disorders |
11/29/2001 | WO2000055159A3 Substituted aza-oxindole derivatives |
11/29/2001 | WO2000047104A9 Antagonists of hmg1 for treating inflammatory conditions |
11/29/2001 | WO2000040722A3 Insulin-synthesis genes |
11/29/2001 | WO2000039114A3 Substituted oximes and hydrazones as neurokinin antagonists |
11/29/2001 | WO2000038666A3 A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES |
11/29/2001 | WO2000010548A3 19-nor-vitamin d3 compounds with calcemic activity |
11/29/2001 | US20010047084 Extendin derivatives |
11/29/2001 | US20010047035 Detecton, treatment and monitoring the patient with poor wound healing ability due to diabetes based on measurement of the breakdown product of nitric oxide (NO) in specimens taken from the patient under controlled conditions |
11/29/2001 | US20010047030 Somatostatin antagonists and agonists that act at the SST subtype 2 receptor |
11/29/2001 | US20010047008 Allosteric adenosine receptor modulators |
11/29/2001 | US20010047002 Squarate derivatives of dihydropyridine NPY antagonists |
11/29/2001 | US20010046993 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists |
11/29/2001 | US20010046963 Inhibiting cyclooxygenase-2 biosynthesis and Nuclear factor kappa B synthesis; treatment of arthritis and Alzheimer's disease; administering in food |
11/29/2001 | US20010046958 Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors |
11/29/2001 | US20010046956 May contain another compound to treat diabetes, sexual dysfunction, atherosclerosis, insulin resistance, impaired glucose tolerance, hypercholesterolemia or hypertriglyceridemia |
11/29/2001 | US20010046533 With natural isomers of reduced folate such as 5-methyl-6(S)-tetrahydrofolic acid, a food preparation, and/or essential nutrient preparation (other than ascorbic acid) in given molar amounts |
11/29/2001 | US20010046496 Administering to the human having a disease associated with leukocyte infiltration of mucosal tissues a humanized immunoglobulin or antigen-binding fragment having binidng specificity for alpha 4 beta 7 integrain |
11/29/2001 | US20010046495 Use of cross-linked, covalently bound urokinase plasminogen activator (scuPAR)-urokinase plasminogen activator receptor (suPAR) complex as a fibrinolytic agent |
11/29/2001 | US20010046490 Cell surface molecule-induced macrophage activation |
11/29/2001 | US20010046489 Stem cells of the islets of langerhans and their use in treating diabetes mellitus |
11/29/2001 | EP1143949A3 19-nor-vitamin d3 compounds with calcemic activity |
11/29/2001 | DE10024939A1 Neue Diphenylmethanderivate für Arzneimittel New diphenylmethane derivatives for pharmaceuticals |
11/29/2001 | CA2429199A1 Drug metabolizing enzymes |
11/29/2001 | CA2410563A1 Methods for preventing strokes by inducing tolerance to e-selectin |
11/29/2001 | CA2410520A1 Mutated eukariotic translation initiation factor 2 alpha kinase 3, eif2ak3, in patients with neonatal insulin-dependent diabetes and multiple epiphyseal dysplasia (wolcott-rallison syndrome) |
11/29/2001 | CA2410338A1 Tyrosine phosphatase inhibitors |
11/29/2001 | CA2409956A1 Use of ciliary neurotrophic factor |
11/29/2001 | CA2409430A1 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as protein kinase modulators |
11/29/2001 | CA2409367A1 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
11/29/2001 | CA2408783A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
11/29/2001 | CA2408739A1 Novel proteins and nucleic acids encoding same, diagnostic and therapeutic uses |
11/29/2001 | CA2408709A1 Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use a modulators of protein kinases |
11/29/2001 | CA2408562A1 Dehydroascorbic acid formulations and uses thereof |
11/29/2001 | CA2408141A1 Neurotransmitter transporters |
11/29/2001 | CA2408140A1 G-protein coupled receptors |
11/29/2001 | CA2408036A1 Combination of growth hormone secretagogues and antidepressants |
11/29/2001 | CA2407964A1 Disulfide derivatives useful for treating allergic diseases |
11/29/2001 | CA2406829A1 Protease inhibitors |
11/29/2001 | CA2380935A1 Caspase inhibitors and uses thereof |
11/28/2001 | EP1158002A1 Human G-protein coupled receptor |
11/28/2001 | EP1157992A1 Dihydro-2,3-Benzodiazepine derivatives |
11/28/2001 | EP1157697A1 Remedies for hyperammonemia |
11/28/2001 | EP1157696A2 Treatment of rumen acidosis with alpha-amylase inhibitors |
11/28/2001 | EP1157695A1 Method of treating obesity using a neurotensin receptor ligand |
11/28/2001 | EP1157104A2 Pyk2 binding proteins |
11/28/2001 | EP1157043A1 Anti-gpr-9-6 and anti-teck antibodies and methods of identifying modulators of gpr-9-6 and teck functions |
11/28/2001 | EP1157040A1 Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction |
11/28/2001 | EP1157024A1 Acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as tace inhibitors |
11/28/2001 | EP1157022A1 Pyridine compounds and their pharmaceutical use |
11/28/2001 | EP1157014A1 Polycyclic 2-amino-dihydrothiazole systems, method for the production thereof and their utilization as medicament |
11/28/2001 | EP1157013A1 Polycyclic thiazole-2-ylides amines, method for the production thereof and their utilization as medicaments |
11/28/2001 | EP1157001A1 Oxamic acids and derivatives as thyroid receptor ligands |
11/28/2001 | EP1157000A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy |
11/28/2001 | EP1156999A1 Method for the preparation of a chiral-beta-amino ester |
11/28/2001 | EP1156820A1 Vascular endothelial growth factor-2 |
11/28/2001 | EP1156795A1 Use of succinic acid or salts thereof and method of treating insulin resistance |
11/28/2001 | EP1156771A2 Interferon tau mutants and methods for making them |
11/28/2001 | EP0914129B1 Use of aspirochlorine or derivatives thereof as immunosuppressive agents |
11/28/2001 | EP0804469B1 T-cell affecting peptides |
11/28/2001 | EP0770068B1 Conformationally rigid bicyclic and adamantane derivatives useful as alpha 2-adrenergic blocking agents |
11/28/2001 | EP0512076B1 Method of treating cancer using structured lipids |
11/28/2001 | CN1324400A Method of screening for large offspring syndrome |
11/28/2001 | CN1324360A Bicyclic nitrogen heterocycles |
11/28/2001 | CN1324353A Amidine derivatives, their preparation and application as medicines and pharmaceutical compositions containing same |
11/28/2001 | CN1324350A Benzoylpyridazines |
11/28/2001 | CN1323794A Novel hetero naphthenic benzcyclobutane and heterocyclo acryl benzcyclobutane compound, their prepn. method and pharmaceutical composites |
11/28/2001 | CN1323625A Hypolycemic traditional Chinese medicine composite |
11/28/2001 | CN1323621A Hypolycemic pellet made of ginseng and largehead atractylodes rhizome |
11/28/2001 | CN1323601A Diebestos treating medicine |
11/28/2001 | CN1323581A Calcium making-up agent material |
11/27/2001 | US6323242 Treatment of disorders secondary to organic impairments |
11/27/2001 | US6323232 Combination therapy for osteoporosis |
11/27/2001 | US6323229 Compounds are useful psychotherapeutics and are potent agonists and/or antagonists of the serotonin 1a (5-ht 1a) and/or serotonin 1d (5-ht 1d) for treatment of hypertension, depression, generalized anxiety disorder |
11/27/2001 | US6323225 Pharmaceutical composition |
11/27/2001 | US6323214 Allosteric adenosine receptor modulators |
11/27/2001 | US6323192 Chromium polynicotinate compositions and uses thereof for absorption of essential metals |
11/27/2001 | US6323178 Beta-lipotropin methods |
11/27/2001 | US6323029 Therapeutic, diagnostic, and research applications for the modulation of glycogen synthase kinase 3 beta expression |
11/27/2001 | US6322976 Compositions and methods of disease diagnosis and therapy |
11/27/2001 | US6322806 Over-coated chewing gum formulations including tableted center |
11/27/2001 | US6322784 Glucocorticoid, a compound which stimulates camp production and compound which upregulates peroxisome proliferator activated receptor .gamma. expression |
11/27/2001 | CA2179712C Crosslinked polymeric ammonium salts |
11/27/2001 | CA2025294C Bile acid derivatives, processes for their preparation, and use as pharmaceuticals |
11/25/2001 | CA2309518A1 Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders |
11/22/2001 | WO2001088533A2 Lipid uptake assays |
11/22/2001 | WO2001088532A2 Improved assay techniques using nematode worms |